world
FDA Allows Philip Morris to Market Zyn Nicotine Pouches With Reduced-Risk Claims but Warns No Tobacco Product Is Safe
The Food and Drug Administration on Tuesday cleared Philip Morris to market 20 Zyn nicotine pouch products as less harmful than cigarettes. The order permits specific claims that switching from cigarettes lowers risks for several major diseases. It expands a January 2025 authorization that allowed sales without the health claims.
UN
cnbc.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The Food and Drug Administration on Tuesday authorized Philip Morris International to market 20 Zyn nicotine pouch products as less harmful than cigarettes. The order permits the products to carry a modified-risk claim stating that switching from cigarettes to Zyn lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
Zyn pouches contain nicotine but not tobacco and are placed between a user's gum and lip.
The FDA had authorized the same 20 products for sale in January 2025 without allowing marketing claims about reduced disease risk. Tuesday's decision extends that approval by permitting the specific lower-risk assertions tied to major smoking-related illnesses.
The products include Zyn Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint and Wintergreen, each available in 3-milligram and 6-milligram nicotine strengths.
The FDA has stated there is no safe tobacco product and that youth and adults who do not use tobacco products should not start. Bloomberg reported the authorization covers 20 Zyn variants for claims regarding lung cancer, stroke, emphysema and other diseases.
The FDA, Philip Morris and the White House did not immediately respond to requests for comment.
